Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.US based drug developer Alexza Pharmaceuticals has refiled the new drug application (NDA) of AZ-004 with the US Food and Drug Administration (FDA) in response to a complete response letter (CRL) obtained in October 2010.
Subscribe to our email newsletter
AZ-004 is indicated as a treatment of agitation in patients with schizophrenia or bipolar disorder.
In the original CRL, the Center for Drug Evaluation and Research of FDA rejected the NDA and asked the company to provide additional data in support of the application.
The refiling of the NDA consists of original data plus new data from a human factors study, stability data from new production batches manufactured late last year, updated manufacturing and controls sections addressing findings from the company’s Pre-Approval Inspection, and updated draft labeling and a comprehensive REMS proposal.